Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves.

Published byΜυρίνα Παπαδάκης Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves."— Presentation transcript:

1 Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic stroke, (e) HF, and (f) hypoglycemia in patients with T2D treated with either acarbose (Acorb.) or sulfonylureas (Sulfo.). Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2018 Endocrine Society None, Volume 103, Issue 10, 02 August 2018, Pages 3611–3619, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves."

Similar presentations

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Schematic representation of the experimental design.

Figure 1 Schematic representation of the experimental design.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.

FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.

Figure 1 Mean (±SE) egg investment in female zebra finches shortly after a second injection with either tetanus toxoid ... Figure 1 Mean (±SE) egg investment.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Source: Figure created by the author based on data ...

Source: Figure created by the author based on data ...
Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.
RCTs: randomized controlled ...

RCTs: randomized controlled ...
Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,

Fig. 1 Graphical representation of improving mortality in stroke patients since the inception of a national stroke ... “Graph courtesy of George Dunn,
Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.
Take home figure The protective role of CNP/NPR-B/NPRC.

Take home figure The protective role of CNP/NPR-B/NPRC.

Similar presentations

Ads by Google